| Filed On | Filing |
|---|---|
| 05 Nov 2026 |
8-K: Results of Operations and Financial Condition
Reached alignment with the FDA on the final design of the ENABLE-2 pivotal Phase 3 trial |
| 14 Oct 2026 |
8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure
Accomplished biopharmaceutical executive with extensive experience in corporate strategy, finance and commercial readiness |
| 05 Aug 2026 |
8-K: Results of Operations and Financial Condition
Announced positive Phase 1 clinical data for ELVN-001 in CML, demonstrating encouraging ELVN-001 efficacy data and a favorable safety and tolerability profile |
| 12 Jun 2026 |
8-K: Entry into a Material Definitive Agreement; Regulation FD Disclosure
Enliven Therapeutics, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several underwriters named in Schedule A (the “Underwriters”), (i) an aggregate of 8,933,334 shares of its common stock, par value $0.0... |
| 11 Jun 2026 |
8-K: Regulation FD Disclosure; Other Events
Enliven Therapeutics Announces Updated Positive Phase 1 Clinical Data and Alignment with FDA on Key Phase 3 Trial Design Components |
| 10 Jun 2026 |
8-K: Amendments to Articles/Bylaws; Change in Fiscal Year; Submission of Matters to a Vote of Security Holders
Enliven Therapeutics, Inc., a corporation organized and existing under the laws of the State of Delaware (the “Corporation”), DOES HEREBY CERTIFY: |
| 07 May 2026 |
8-K: Results of Operations and Financial Condition
Initiation of the Phase 3 ENABLE-2 pivotal trial of ELVN-001 expected in the second half of 2026 |
| 03 Mar 2026 |
8-K: Results of Operations and Financial Condition
Initiation of the Phase 3 ENABLE-2 pivotal trial of ELVN-001 expected in the second half of 2026 |
| 07 Jan 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
Scott Garland, a seasoned biopharma executive with a strong track record of leading successful |
| 11 Dec 2025 |
8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure
1. Purpose. The purpose of this 2025 Inducement Equity Incentive Plan (the “Plan”) of Enliven Therapeutics, Inc., a Delaware corporation (the “Company”), is to attract and retain the best available personnel for positions of substantial ... |
| 12 Nov 2025 |
8-K: Results of Operations and Financial Condition
Completed enrollment of the randomized Phase 1b cohorts of the ongoing ENABLE trial of ELVN-001 in CML |
| 13 Aug 2025 |
8-K: Results of Operations and Financial Condition
Announced positive data from the Phase 1 clinical trial of ELVN-001 in CML, reporting a cumulative MMR rate of 47% with 32% of patients achieving MMR by 24 weeks and demonstrating a favorable safety and tolerability profile across all do... |
| 25 Jun 2025 |
8-K: Submission of Matters to a Vote of Security Holders
Enliven Therapeutics, Inc. (the “Company”) held its Annual Meeting of Stockholders (the “Annual Meeting”) on June 24, 2025. The matters voted upon at the Annual Meeting and the voting results for each proposal are set forth below. |
| 16 Jun 2025 |
8-K: Entry into a Material Definitive Agreement; Other Events
Enliven Therapeutics, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several underwriters named in Schedule A (the “Underwriters”), (i) an aggregate of 8,394,737 shares of its common stock, par value $0.0... |
| 13 Jun 2025 |
8-K: Regulation FD Disclosure; Other Events
Reported cumulative MMR rate of 47% (25 of 53) by 24 weeks with 32% (13 of 41) of patients achieving |
| 14 May 2025 |
8-K: Results of Operations and Financial Condition
Updated data from the Phase 1 ENABLE clinical trial of ELVN-001 in CML to be presented at the EHA 2025 Congress in June |
| 13 Mar 2025 |
8-K: Results of Operations and Financial Condition
Updated Phase 1 data for ELVN-001 expected mid-2025 as positive enrollment momentum continues |
| 13 Nov 2024 |
8-K: Results of Operations and Financial Condition
Announced positive data from the Phase 1 clinical trial of ELVN-001 in CML, reporting a cumulative MMR rate of 44% (8/18) by 24 weeks and showing that ELVN-001 remains well-tolerated with no dose reductions |
| 13 Aug 2024 |
8-K: Results of Operations and Financial Condition
Dosed the first patient in the Phase 1b arm of the clinical trial evaluating ELVN-001 in patients with CML that is relapsed, refractory or intolerant to available TKIs |
| 18 Jun 2024 |
8-K: Departure/Election of Directors or Officers; Compensation; Amendments to Articles/Bylaws; Change in Fiscal Year +1 more
1. Purpose. The purpose of this Amended and Restated 2020 Equity Incentive Plan (the “Plan”) of Enliven Therapeutics, Inc., a Delaware corporation (the “Company”), is to advance the interests of the Company’s stockholders by enhancing th... |
Loading...